Trial · NCT04024228
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Geometric Mean Titers (GMTs) of Influenza Antibodies in Participants Aged 60-64 Years and Greater Than or Equal to (>=) 65 Years | Day 28 post-vaccination | Analysis was performed on FAS population. Here, 'Number analyzed' = participants with available data for each specified category. | titers | GEOMETRIC_MEAN |
| SECONDARY | Geometric Mean Titers of Influenza Antibodies Pre-and Post-Vaccination in All Age Group Participants | Day 0 (pre-vaccination), Day 28 (post-vaccination) | Analysis was performed on FAS population. Here, 'Number analyzed' = participants with available data for each specified category. | titers | GEOMETRIC_MEAN |
| SECONDARY | Geometric Mean Titers of Influenza Antibodies Pre- and Post-Vaccination in Participants Aged 60-64 Years and >=65 Years | Day 0 (pre-vaccination), Day 28 (post-vaccination) | Analysis was performed on FAS population. Here, 'Number analyzed' = participants with available data for each specified category. | titers | GEOMETRIC_MEAN |
| SECONDARY | Geometric Mean Titer Ratios (GMTRs) of Influenza Antibodies in All Age Group Participants | Day 0 (pre-vaccination), Day 28 (post-vaccination) | Analysis was performed on FAS population. Here, 'Number analyzed' = participants with available data for each specified category. | ratio | GEOMETRIC_MEAN |
| SECONDARY | Geometric Mean Titer Ratios of Influenza Antibodies in Participants Aged 60-64 Years and >=65 Years | Day 0 (pre-vaccination), Day 28 (post-vaccination) | Analysis was performed on FAS population. Here, 'Number analyzed' = participants with available data for each specified category. | ratio | GEOMETRIC_MEAN |
| SECONDARY | Percentage of Participants (All Age Group Participants) With Neutralizing Antibody Titers >=40 (1/Dilution) | Day 28 post-vaccination | Analysis was performed on FAS population. Here, 'Number analyzed' = participants with available data for each specified category. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants (Aged 60-64 Years and >=65 Years) With Neutralizing Antibody Titers >=40 (1/Dilution) | Day 28 post-vaccination | Analysis was performed on FAS population. Here, 'Number analyzed' = participants with available data for each specified category. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants (All Age Group Participants) Achieving Seroconversion Against Antigens | Day 28 post-vaccination | Analysis was performed on FAS population. Here, 'Number analyzed' = participants with available data for each specified category. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants (Aged 60-64 Years and >=65 Years) Achieving Seroconversion Against Antigens | Day 28 post-vaccination | Analysis was performed on FAS population. Here, 'Number analyzed' = participants with available data for each specified category. | percentage of participants | NUMBER |
| SECONDARY | Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs) | Within 30 minutes post-vaccination | Analysis was performed on safety analysis set (SafAS) which included participants who had received the study vaccine and had any safety data available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Reporting Solicited Injection Site Reactions | Within 7 days post-vaccination | Analysis was performed on the SafAS population. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Reporting Solicited Systemic Reactions | Within 7 days post-vaccination | Analysis was performed on the SafAS population. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Reporting Unsolicited Adverse Events (AEs) | Within 28 days post-vaccination | Analysis was performed on SafAS population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Reporting Serious Adverse Events (SAEs) Including Adverse Event of Special Interest (AESIs) | From Day 0 up to 6 months post-vaccination | Analysis was performed on the SafAS population. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04024228/outcomes